BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Cancelled)

3. - 6. (Cancelled)

7. (Currently amended) A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor wherein said disorder is selected from the group consisting essentially of: schizophrenia and depression; in a patient in need thereof which comprises administering to said patient a therapeutically effective amount of a compound of formula I.



(I)

wherein

A is N;

X is CR_{11} ~~or N~~;

Y is ~~CR_7 or~~ N ~~with the proviso that when X is N, then Y must be CR_7;~~

R_1 is H, C_1-C_6alkylcarbonyl, C_1-C_6alkylcarbonyloxy or an C_1-C_6alkyl, C_1-C_6alkenyl, C_1-C_6alkynl or cycloheteroalkyl group each optionally substituted;

R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1-C_6alkyl group;

~~R_7 and~~ R_{11} ~~are each independently~~ is H, halogen or an C_1-C_6alkyl, aryl, heteroaryl or C_1-C_6alkoxy group each optionally substituted;

R_8 is an C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted;

R_9 is H, halogen or an C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkenyl, aryl or heteroaryl group each optionally substituted;

R_{10} is H, OH or an optionally substituted C_1-C_6alkoxy group;

m is an integer of 2;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond ~~or a double bond~~; or

a pharmaceutically acceptable salt thereof.

12. (Cancelled)

14. - 17. (Cancelled)

18. (Currently Amended) A method for the preparation of a compound of formula I.



(I)

wherein

A is N;

X is CR_{11} ~~or N~~;

Y is ~~CR_7 or~~ N ~~with the proviso that when X is N, then Y must be CR_7~~;

R_1 is C_1-C_6alkylcarbonyl, C_1-C_6alkylcarbonyloxy or an C_1-C_6alkyl, C_1-C_6alkenyl, C_1-C_6alkynl or cycloheteroalkyl group each optionally substituted;

R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1-C_6alkyl group;

~~R_7 and~~ R_{11} ~~are each independently~~ is H, halogen or an C_1-C_6alkyl, aryl, heteroaryl or alkoxy group each optionally substituted;

R_8 is an C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted;

R_9 is H, halogen or an C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkenyl, aryl or heteroaryl group each optionally substituted;

R_{10} is H, OH or an optionally substituted C_1-C_6alkoxy group;

m is an integer of 2;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond ~~or a double bond~~

said method which comprises reacting a compound of formula Ia



(Ia)

wherein A, X, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, m and n are as defined hereinabove for formula I with a compound R_1-Hal wherein R_1 is as defined hereinabove for formula I and Hal is Cl, Br or I.

19. (Currently Amended) A compound of formula I



(I)

wherein

A is N;

X is CR_{11};

Y is N;

R_1 is H, C_1-C_6alkylcarbonyl, C_1-C_6alkylcarbonyloxy or an C_1-C_6alkyl, C_1-C_6alkenyl, C_1-C_6alkynl or cycloheteroalkyl group each optionally substituted;

R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1-C_6alkyl group;

R_{11} is H, halogen or an C_1-C_6alkyl, aryl, heteroaryl or C_1-C_6alkoxy group each optionally substituted;

R_8 is an C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted;

R_9 is H, halogen or an C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkenyl, aryl or heteroaryl group each optionally substituted;

R_{10} is H, OH or an optionally substituted C_1-C_6alkoxy group;

m is an integer of 2;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond ~~or a double bond~~; or

a pharmaceutically acceptable salt thereof.

20. (Previously presented) The compound according to claim 19 wherein R_8 is an optionally substituted phenyl group.

21. (Previously presented) The compound according to claim 19 selected from the group consisting of:

1-(phenylsulfonyl)-5-piperazin-1-yl-1H-indazole;

1-(phenylsulfonyl)-6-piperazin-1-yl-1H-indazole;

1-[(2-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

methyl 4-[(5-piperazin-1-yl-1H-indazol-1-yl)sulfonyl]phenyl ether;

1-phenylsulfonyl-4-(4-propylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-piperazin-1-yl-1H-indazole;

1-phenylsulfonyl-4-(4-phenethylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-[4-(3-phenylpropyl)-piperazin-1-yl]-1H-indazole; and
the pharmaceutically acceptable salts thereof.

22. (Currently Amended) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I.



(I)

wherein

A is N;

X is CR_{11};

Y is N;

R_1 is H, C_1-C_6alkylcarbonyl, C_1-C_6alkylcarbonyloxy or an C_1-C_6alkyl, C_1-C_6alkenyl, C_1-C_6alkynl or cycloheteroalkyl group each optionally substituted;

R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1-C_6alkyl group;

R_{11} is H, halogen or an C_1-C_6alkyl, aryl, heteroaryl or C_1-C_6alkoxy group each optionally substituted;

R_8 is an C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted;

R_9 is H, halogen or an C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkenyl, aryl or heteroaryl group each optionally substituted;

R_{10} is H, OH or an optionally substituted C_1-C_6alkoxy group;

m is an integer of 2;

n is O or an integer of 1, 2 or 3; and

---- represents a single bond ~~or a double bond~~; or

a pharmaceutically acceptable salt thereof.

23. (Previously presented) The composition according to claim 22 having a compound of formula I selected from the group consisting of:

1-(phenylsulfonyl)-5-piperazin-1-yl-1H-indazole;

1-(phenylsulfonyl)-6-piperazin-1-yl-1H-indazole;

1-[(2-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

methyl 4-[(5-piperazin-1-yl-1H-indazol-1-yl)sulfonyl]phenyl ether;

1-phenylsulfonyl-4-(4-propylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-piperazin-1-yl-1H-indazole;

1-phenylsulfonyl-4-(4-phenethylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-[4-(3-phenylpropyl)-piperazin-1-yl]-1H-indazole; and

the pharmaceutically acceptable salts thereof.